论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
在中国是否有 β-内酰胺类抗生素耐药的产脓链球菌出现?
Received 9 May 2020
Accepted for publication 25 June 2020
Published 14 July 2020 Volume 2020:13 Pages 2323—2327
DOI https://doi.org/10.2147/IDR.S261975
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Professor Suresh Antony
Abstract: Streptococcus pyogenes is regarded as susceptible to β-lactam antibiotics. The guidelines of the Clinical and Laboratory Standards Institute (CLSI) are widely recognized and have long-recommended penicillin for treatment of S. pyogenes infections. There is no CLSI guideline for the treatment of S. pyogenes infections that have intermediate susceptibility or resistance to penicillin. However, there have been several reports of S. pyogenes isolates that are nonsusceptible or even resistant to β-lactam antibiotics, mostly from Chinese journals. The purpose of this commentary is to show data from the literature which suggests the presence of S. pyogenes isolates that are not susceptible to β-lactam antibiotics and whether these strains are really nonsusceptible to β-lactam antibiotics and the presence of mutation in the pbp2x gene requires further research and confirmation.
Keywords: Streptococcus pyogenes , GAS, β-lactam, antibiotic resistance, China
